Displaying 37 - 48 of 132
Viral Hepatitis
1

GSK: "Looking To The Future Of Hepatitis B: An Expert Review Of Quantitative Hepatitis B Surface Antigen Assessment” - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Albireo Pharma, an Ipsen Company: “New Horizons in cholestatic liver disease” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Ipsen: "Scratching beyond the surface in PBC: From current unmet medical needs to future prospects" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Mirum Pharmaceuticals, Inc: "Meet the Experts in Cholestatic Liver Disease" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Displaying 37 - 48 of 132